The goal of the present study was to determine if the expression of metallothionein isoform 3 (MT-3) might serve as a biomarker for human bladder cancer. To accomplish this goal, we defined the localization and expression of MT-3 protein and mRNA using fresh and archival biopsy specimens obtained from patients undergoing differential diagnosis for a variety ofbladder disorders. We used immiunohistochemistry, immunoblot, and RT-PCR analysis to define the localization and expression of MT-3 protein and mRNA. Immunohistochemical analysis disdosed no immunoreactivity for MT-3 in normal bladder cells. The absence of MT-3 expression in the normal bladder was firther confinned by demonstrating that MT-3 mRNA could not be detected using reverse transcriptase-polymerase chain reaction (RT-PCR) or MT-3 protein using immunoblot. Immunohistochemistry also disdosed no immunoreactivity for MT-3 in archival biopsy specimens from patients with interstitial cystitis and related disorders. Immunohistochemical analysis demonstrated that MT-3 was expressed in carcinoma in situ (CIS), high-grade bladder cancer, low-grade bladder cancer, and dysplastic lesions. MT-3 immunostaining was intense in both CIS and high-grade bladder cancer, and low to moderate in low-grade bladder cancer and dysplastic lesions. We determined MT-3 mRNA expression in a subset of these bladder cancer specimens; expression was elevated as compared to that of the housekeeping gne, I0-actin. The cDNA from the RT-PCR reaction primed for MT-3 contained a Fold restriction site, a site unique for MT-3 as compared to other MT family members. In condusion, this study demonstrates that MT-3 is up-regulated in human bladder cancer and that this up-regulation increases with increasing tmor grade. The finding that MT-3 expression is minimal in normal bladder sugests that MT-3 might be developed into an effective biomarker for bladder cancer.
The goal of the present study was to determine if the expression of metallothionein isoform 3 (MT-3) might serve as a biomarker for human bladder cancer. To accomplish this goal, we defined the localization and expression of MT-3 protein and mRNA using fresh and archival biopsy specimens obtained from patients undergoing differential diagnosis for a variety ofbladder disorders. We used immiunohistochemistry, immunoblot, and RT-PCR analysis to define the localization and expression of MT-3 protein and mRNA. Immunohistochemical analysis disdosed no immunoreactivity for MT-3 in normal bladder cells. The absence of MT-3 expression in the normal bladder was firther confinned by demonstrating that MT-3 mRNA could not be detected using reverse transcriptase-polymerase chain reaction (RT-PCR) or MT-3 protein using immunoblot. Immunohistochemistry also disdosed no immunoreactivity for MT-3 in archival biopsy specimens from patients with interstitial cystitis and related disorders. Immunohistochemical analysis demonstrated that MT-3 was expressed in carcinoma in situ (CIS), high-grade bladder cancer, low-grade bladder cancer, and dysplastic lesions. immunostaining was intense in both CIS and high-grade bladder cancer, and low to moderate in low-grade bladder cancer and dysplastic lesions. We determined MT-3 mRNA expression in a subset of these bladder cancer specimens; expression was elevated as compared to that of the housekeeping gne, I0-actin. The cDNA from the RT-PCR reaction primed for MT-3 contained a Fold restriction site, a site unique for MT-3 as compared to other MT family members. In condusion, this study demonstrates that MT-3 is up-regulated in human bladder cancer and that this up-regulation increases with increasing tmor grade. The finding that MT-3 expression is minimal in normal bladder sugests that The progress against bladder cancer over the last 20 years and the current diagnosis and treatment strategies for managing the disease have been the subject of recent reviews (1, 2) . In the United States over 54,000 new cases of bladder cancer are diagnosed each year and more than 12,000 annual deaths result from the disease (3) . Bladder cancer is the fifth most common cancer in the United States, and approximately 15-30% of bladder tumors show grade and stage progression (4) . Metastasis is the main cause of death in bladder cancer patients, and approximately 50% of patients who present with muscleinvasive bladder tumors die from metastatic disease (5) . The number of cases of bladder cancer has increased each year for the past 20 years while the mortality attributed to the disease has remained relatively constant (1) .
Epidemiologically, bladder cancer represents one of the first cancers in which environmental carcinogens were found to play the major role in causing the disease. In 1895, Rehn (6) observed an association between exposure to aromatic amines and bladder cancer in factory workers. This association was confirmed in both animal models and in humans working in industries that involved exposure to aromatic amines (7, 8 ). Many studies have described an association between cigarette smoking and bladder cancer; some reports suggested a 2-to 4-fold increased risk and that 50% of the bladder cancers in men would not occur in the absence of cigarette smoking (9, 10) . The majority of the remaining bladder cancers are believed to be caused by industrial or agricultural carcinogens. The number of cigarettes smoked, degree of inhalation, type of tobacco, use of filters, and smoking cessation all have specific relationships to the development of bladder cancer (11) . There are no widely accepted tumor markers that allow widespread screening for the early presence of bladder cancer or for the detection and monitoring of advanced metastatic disease; however, evidence suggests that such markers could impact on reducing the mortality of this disease [reviewed by Lamm (1) and Droller (4] .
The need for effective biomarkers for the detection of bladder cancer led us to define the expression of metallothionein isoform 3 (MT-3) in the normal and cancerous bladder. The rationale for this examination comes from recent findings showing that MT-3 is expressed in the epithelial components of both the normal kidney and prostate gland, with altered expression in organ-derived cancers (12) (13) (14) . The finding of MT-3 expression in these organs was unexpected because the recently characterized MT-3 gene was initially reported to have a highly restricted expression pattern confined to neural tissues (15) . The finding that MT-3 was expressed in other tissues of the urogenital system motivated the expansion of this analysis to determine if MT-3 is expressed in the bladder, and if this expression is altered in epithelial cell-derived cancers.
Materials and Methods
Bladdr specimensfor immunohistochemical analysis of MT-3 expression. For the immunohistochemical analysis of MT-3 expression, we obtained biopsy tissues from paraffin blocks that originated from previously completed patient diagnostic procedures. These biopsy specimens are archived, after completion of diagnostic procedures, in the Department of Pathology of the West Virginia University Hospitals (Morgantown, WV). To define the immunohistochemical expression of MT-3 in control and noncancerous lesions of the bladder, we utilized a set of paraffin-embedded tissue samples that had been used previously to determine heat shock protein expression in the bladder of patients with interstitial cystitis (IC) and IC-like syndromes (16) (17) (18) Bladder specimens for analysis ofMT-3 mRNA expression. To determine the MT-3 mRNA expression in control bladder, we used three independent samples of total RNA prepared from undiseased adult bladder from the previous studies on IC (16) (17) (18) and added three additional samples for the present analysis. These total RNA samples were prepared from six independent specimens of undiseased adult bladder obtained from biopsy or surgical specimens after the completion of diagnostic protocols. For the determination of MT-3 mRNA expression in TCC, we isolated total RNA from full-thickness (10 pm) sections from a subset of the paraffin-embedded tissues to determine the immunohistochemical expression of MT-3 in TCC. We chose samples where the malignant lesion made up over 85% of the section.
Immunohistochemical localization of MT-3. We generated the affinity purified antibody against human MT-3 using the dodecapeptide GGEAAEAEAEKC (corresponding to MT-3 amino acids 53-64, which contain the MT-3 unique amino acid insert) conjugated through the C-terminal cysteine SH group to keyhole limpet hemocyanine using maleimidobenzoyl-N-hydroxysuccinimide ester, as described previously (13, 14) . This antibody was used to immunize New Zealand white rabbits. The MT-3 antibody was affinity purified using the dodecapeptide linked to SulfoLink gel (Pierce, Rockford, IL) through the C-terminal cysteine residue. Archival bladder specimens were routinely fixed in 10% neutral buffered formalin for 16-18 hr. All tissues were transferred to 70% ethanol and dehydrated in 100% ethanol. Dehydrated tissues were cleared in xylene, infiltrated, and embedded in paraffin. We cut serial sections at 3-5 pm for use in immunohistochemical protocols. Before immunostaining, sections were pretreated in a microwave at 700 W in 10 mM citrate buffer (pH 6.0) for 5 min. The sections were allowed to cool for 5 min at room temperature, then microwaved again for 5 min and immersed into distilled water. The affinity purified primary anti-MT-3 antibody was localized using the avidin-biotin-peroxidase complex (ABC) procedure (BioGenex optimax immunostainer; BioGenex, Inc., San Ramon, CA) using diaminobenzidine for visualization ( The samples were centrifuged through a 10-kD molecular weight cutoff centrifuge filter (Micron Separations, Westboro, MA). Volumes of filtrate representing 6 pg protein were diluted to 75 pL with PBS and mixed with an equal volume of 3% glutaraldehyde to enhance detection of MT-3. We applied 100 pL of this mixture (2 pg total protein) to a dot-blot apparatus with a polyvinylidine difluoride membrane. Samples were allowed to flow through the apparatus by gravity, then washed 2 times with PBS. After blocking with 3% bovine serum albumin in PBS, the membrane was soaked in primary antibody (4.5 pg/mL, 1% BSA in PBS) for 2 hr. We washed the membrane 3 times with PBS, and we added alkaline phosphataseconjugated secondary antibody (Promega, Madison, WI) at a 1:500 dilution. Antibody complexes were visualized using the alkaline phosphatase kit III (Vector Laboratories Inc., Burlingame, CA). We applied standard curves of the conjugated synthetic peptide (Sigma Chemical Co., St. Louis, MO) to each blot. MT-3 protein was quantified by comparing the optical density of the sample dots to the standard MT-3 curve using KS 400 image analysis software. This assay has detection limits in the range of 0.5-2.0 pg MT-3 protein.
Results
Localization and expression ofMT-3 in the blader from controls andpatients with IC and related disorders. In previous studies, the human kidney has been shown to be immunoreactive for MT-3 protein and to express both MT-3 mRNA and protein by RT-PCR and Western analysis (12, 13) . For the immunohistochemical analysis of MT-3 expression in the normal bladder, we included sections of human kidney as a positive control during each automated immunohistochemical sequence ( Figure 1A) . The indusion of a positive control within each run was especially important in this instance because none of the cell types present in the samples of normal control bladder demonstrated convincing immunoreactivity for MT-3 under identical conditions of analysis ( Figure iB) . As compared to a negative control, where MT-3 antibody was deleted from the reaction sequence, MT-3 immunoreactivity in the normal bladder was only nominally, if at all, above background levels (data not shown). This finding is one indication Environmental Health Perspectives * VOLUME 108 NUMBER 5 May 2000that the normal human bladder has a very low expression of MT-3. To further define the level of expression of MT-3 in the normal bladder, we isolated total RNA and protein from six samples of control bladder (four females and two males). We used the isolated RNA and proteins to determine the expression of MT-3 mRNA and protein, respectively. The expression of MT-3 mRNA was not detected in any of the six control bladder samples at 35 cycles of nonnested RT-PCR and total RNA inputs of 0.5 pg (Figure 2 ). These identical total RNA samples yielded strong reaction products for the housekeeping gene, P-actin, at 35 reaction cycles and equal total RNA inputs. As an additional control, we also obtained strong reaction products for MT-3 mRNA from total RNA samples from human kidney at 35 cycles and equal total RNA inputs ( Figure 2) . Extension Localization and expression ofMT-3 in the bladder from patients with transitional cell carcinoma. In contrast to control urothelium, MT-3 immunoreactivity was demonstrated in LG TCC (Figure IC) , HG TCC ( Figure 1D ), and in CIS ( Figure 1E ) of the human bladder. The majority of MT-3 staining within tumors was cytoplasmic. Some tumors, both LG TCCs and HG TCCs, also demonstrated strong nuclear localization ( Figure IF) . Several of the samples from each tumor grade also had areas of dysplasia in addition to the carcinoma. In general, although the intensity of MT-3 immunoreactivity within the dysplastic regions was less than that of the corresponding malignant lesion, there were examples within each tumor grade where the staining was of moderate intensity. The MT-3 immunostaining within these dysplastic areas appeared elevated over that of normal urothelium (data not shown). Although present in only a few samples, there was also a tendency for weak MT-3 immunoreactivity within Brunn's nests and in areas of cystitis cystica.
In all cases, MT-3 immunoreactivity was diffuse and was localized to the cytoplasm of the cells and, although variable in intensity among the tumor specimens, all malignant lesions appeared to be immunoreactive for MT-3, albeit a few low-grade lesions only weakly. When the qualitative visual observation of MT-3 immunoreactivity was blinded and quantified as a function of tumor grade, the intensity of MT-3 immunostaining increased as a function of tumor grade (Table  1) . When we examined the immunostaining The total RNA input was 0.5 pg and the reaction products were removed at 35 cycles. VOLUME 1081 NUMBER 5 May 2000 * Environmental Health Perspectives results for the biologic classes, benign urothelium, dysplastic urothelium, LG-TCC, HG-TCC, and CIS using the Kolmogorov-Smirnov one-sample test and Systat software (SPSS, Inc., Chicago, IL), we found significant differences between all groups (two-sided probability > 0.003). Thus, increased MT-3 immunoreactivity and the malignant phenotype demonstrated a consistent positive correlation in the human bladder.
We determined the expression of MT-3 mRNA by nested RT-PCR in a subset of the samples used for the determination of MT-3 immunoreactivity. We evaluated these fullthickness sections of paraffin-embedded tissue by microscopic examination, and we selected those where the malignant lesion made up > 85% of the tissue sample. This restriction allowed total RNA to be prepared from 16 LG TCCs, 15 HG TCCs, and 5 CISs. In all cases, RT-PCR analysis resulted in a reaction product of the expected number of base pairs (an example for each tumor grade shown in Figure 3 ). Each sample also expressed P~-actin mRNA, a housekeeping gene commonly utilized to control for total RNA integrity and to make comparisons of gene expression patterns by comparison of relative optical densities. In addition, the MT-3 reaction product contains a FokI restriction site not present in any other MT gene. An RT-PCR product from each tumor grade was subject to restriction cutting by FokI and in each case we obtained cleavage products of the expected size (e.g., Figure 4 ). Together, these findings provide supporting evidence that the MT-3 antibody detects MT-3 protein expression in human bladder cancer. The results also demonstrated that the relative expression of the MT-3 reaction product was greater than that of the 1-actin housekeeping gene (Table 2) . This is based on the relative comparison of the integrated optical densities of the 1B-actin and MT-3 reaction products. For the 36 samples of bladder cancer, the intensity of the MT-3 RT-PCR product bands was approximately 60% of that of the P-actin housekeeping gene ( Table 2) . We analyzed the MT-3 reaction products after 22 cycles of nested RT-PCR and we analyzed the ,B-actin after 35 cycles; this indicates a greater expression of immunoreactivity was greatest in CIS. This is important because improvements in the treatment of superficial bladder cancer have had a great impact on disease progression. As reviewed by Lamm (1), BCG immunotherapy has radically changed the management of CIS. Before 1983, 54% of patients with CIS developed muscle-invasive disease within 5 years. However, with the advent of BCG therapy, 70% or more patients had a complete response, and 65% of complete responders remained disease free for 5 years. With improved BCG maintenance schedules, these numbers are now at 83 and 80%, respectively. Unlike other cancers, CIS of the bladder is a highly malignant, aggressive neoplasm. Thus, a biomarker to detect bladder cancer in its earliest stage, when the lesion is still superficial, has the potential to have a large impact on preventing disease progression. Lastly, the characteristics of both the MT-3 protein and the MT-3 gene sequence are amenable to the development of probes for assays that could be utilized on the urine or bladder washings from individuals potentially exposed to environmental or occupational agents that are bladder carcinogens. The eight-amino-acid sequence used to raise the present antibody is unique among the members of the MT gene family and, based on the current results, appears to have good antigenicity for raising an antibody of high titer and specificity. This would be necessary to extend the current finding to the development of an immunoassay for MT-3 that could be used in large-scale screening protocols. This unique sequence should also allow the generation of monodonal antibodies against the MT-3 protein. The sequence of the MT-3 gene also has sufficient sequence divergence in the 5' and 3' untranslated regions to develop specific primers for the RT-PCR analysis of MT-3 mRNA. Although probably not applicable to large-scale screening protocols, such reagents could be useful in monitoring for the presence of malignant cells in bladder washings from individuals with a disease history.
